{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T07:56:35Z","timestamp":1771919795315,"version":"3.50.1"},"reference-count":148,"publisher":"Georg Thieme Verlag KG","issue":"07","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Semin Thromb Hemost"],"published-print":{"date-parts":[[2021,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The ability of aspirin to inhibit platelet aggregation has positioned this agent within the most frequently used drugs worldwide. The aim of this article is to review the contemporary clinical use of aspirin and also to discuss unresolved issues not yet translated into clinical practice. Results from several clinical trials have led to strong guideline recommendations for aspirin use in the acute management and secondary prevention of cardiovascular disease. On the contrary, guidelines regarding aspirin use as primary prevention of cardiovascular disease are almost conservative, supported by recent trials reporting that the bleeding risk outweighs the potential benefits in most patients. In pregnancy, aspirin has proved efficient in preventing preeclampsia and small-for-gestational-age births in women at high risk, and is hence widely recommended in clinical guidelines. Despite the vast amount of clinical data on aspirin, several unresolved questions remain. Randomized trials have reported that aspirin reduces the risk of recurrent venous thromboembolism, but the clinical relevance remains limited, because direct oral anticoagulants are more effective. Laboratory studies suggest that a twice-daily dosing regimen or evening intake may lead to more efficient platelet inhibition, and the potential clinical benefit of such strategies is currently being explored in ongoing clinical trials. Enteric-coated formulations of aspirin are frequently used, but it remains unclear if they are safer and as efficient as plain aspirin. In the future, aspirin use after percutaneous coronary interventions might not be mandatory in patients who also need anticoagulant therapy, as several trials support shorter aspirin duration strategies. On the other hand, new treatment indications for aspirin will likely arise, as there is growing evidence that aspirin may reduce the risk of colorectal cancer and other types of cancer.<\/jats:p>","DOI":"10.1055\/s-0041-1726096","type":"journal-article","created":{"date-parts":[[2021,6,15]],"date-time":"2021-06-15T22:42:07Z","timestamp":1623796927000},"page":"800-814","source":"Crossref","is-referenced-by-count":23,"title":["Contemporary Clinical Use of Aspirin: Mechanisms of Action, Current Concepts, Unresolved Questions, and Future Perspectives"],"prefix":"10.1055","volume":"47","author":[{"given":"Mikael","family":"Christiansen","sequence":"additional","affiliation":[{"name":"Department of Clinical Biochemistry, Regional Hospital in Horsens, Horsens, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erik Lerkevang","family":"Grove","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark"},{"name":"Department of Clinical Medicine, Faculty of Health, Aarhus University, Aarhus, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne-Mette","family":"Hvas","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine, Faculty of Health, Aarhus University, Aarhus, Denmark"},{"name":"Department of Clinical Biochemistry, Aarhus University Hospital, Aarhus, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2021,6,15]]},"reference":[{"key":"ref1","first-page":"1","article-title":"The first 3500 years of aspirin history from its roots - a concise summary","volume":"113","author":"M R Montinari","year":"2019","journal-title":"Vascul Pharmacol"},{"issue":"05","key":"ref2","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1111\/bjh.14520","article-title":"The aspirin story - from willow to wonder drug","volume":"177","author":"M JR Desborough","year":"2017","journal-title":"Br J Haematol"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1136\/bmj.1.5905.436","article-title":"A randomized controlled trial of acetyl salicylic acid in the secondary prevention of mortality from myocardial infarction","volume":"1","author":"P C Elwood","year":"1974","journal-title":"BMJ"},{"issue":"07","key":"ref4","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1056\/NEJMoa1704559","article-title":"Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia","volume":"377","author":"D L Rolnik","year":"2017","journal-title":"N Engl J Med"},{"issue":"13","key":"ref5","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1161\/CIRCULATIONAHA.114.008828","article-title":"Aspirin for the prevention of recurrent venous thromboembolism: the INSPIRE collaboration","volume":"130","author":"J Simes","year":"2014","journal-title":"Circulation"},{"issue":"05","key":"ref6","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.annonc.2020.02.012","article-title":"Aspirin and the risk of colorectal and other digestive tract cancers: an updated meta-analysis through 2019","volume":"31","author":"C Bosetti","year":"2020","journal-title":"Ann Oncol"},{"issue":"05","key":"ref7","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1055\/s-0039-1687905","article-title":"Primary prevention of cardiovascular events with aspirin: toward more harm than benefit - a systematic review and meta-analysis","volume":"45","author":"M Christiansen","year":"2019","journal-title":"Semin Thromb Hemost"},{"issue":"02","key":"ref8","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1007\/s11239-019-01997-5","article-title":"The dawn of aspirin free strategy after short term dual antiplatelet for percutaneous coronary intervention: meta-analysis of randomized controlled trials","volume":"49","author":"M Osman","year":"2020","journal-title":"J Thromb Thrombolysis"},{"issue":"04","key":"ref9","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1055\/s-2007-996108","article-title":"Aspirin and platelets: the antiplatelet action of aspirin and its role in thrombosis treatment and prophylaxis","volume":"23","author":"K Schr\u00f6r","year":"1997","journal-title":"Semin Thromb Hemost"},{"issue":"02","key":"ref10","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1042\/bj2590315","article-title":"The eicosanoids and their biochemical mechanisms of action","volume":"259","author":"W L Smith","year":"1989","journal-title":"Biochem J"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/S0140-6736(06)68040-9","article-title":"Aspirin resistance","volume":"367","author":"G J Hankey","year":"2006","journal-title":"Lancet"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/0049-3848(80)90066-3","article-title":"Low dose aspirin and inhibition of thromboxane B2 production in healthy subjects","volume":"17","author":"C Patrono","year":"1980","journal-title":"Thromb Res"},{"issue":"01","key":"ref13","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/0304-4165(89)90051-2","article-title":"Fractional conversion of thromboxane B2 to urinary 11-dehydrothromboxane B2 in man","volume":"992","author":"G Ciabattoni","year":"1989","journal-title":"Biochim Biophys Acta"},{"issue":"03","key":"ref14","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/0049-3848(77)90185-2","article-title":"Differential formation of prostacyclin (PGX or PGI2) by layers of the arterial wall. An explanation for the anti-thrombotic properties of vascular endothelium","volume":"11","author":"S Moncada","year":"1977","journal-title":"Thromb Res"},{"issue":"03","key":"ref15","doi-asserted-by":"crossref","first-page":"390","DOI":"10.7326\/0003-4819-104-3-390","article-title":"Aspirin and the stomach","volume":"104","author":"D Y Graham","year":"1986","journal-title":"Ann Intern Med"},{"issue":"08","key":"ref16","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1111\/jth.12637","article-title":"Reappraisal of the clinical pharmacology of low-dose aspirin by comparing novel direct and traditional indirect biomarkers of drug action","volume":"12","author":"P Patrignani","year":"2014","journal-title":"J Thromb Haemost"},{"issue":"19","key":"ref17","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1056\/NEJM198411083111902","article-title":"Dose-related kinetics of aspirin. Presystemic acetylation of platelet cyclooxygenase","volume":"311","author":"A K Pedersen","year":"1984","journal-title":"N Engl J Med"},{"issue":"08","key":"ref18","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/nsb0895-637","article-title":"The structural basis of aspirin activity inferred from the crystal structure of inactivated prostaglandin H2 synthase","volume":"2","author":"P J Loll","year":"1995","journal-title":"Nat Struct Biol"},{"issue":"22","key":"ref19","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1056\/NEJMra052717","article-title":"Low-dose aspirin for the prevention of atherothrombosis","volume":"353","author":"C Patrono","year":"2005","journal-title":"N Engl J Med"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"234S","DOI":"10.1378\/chest.126.3_suppl.234S","article-title":"Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy","volume":"126","author":"C Patrono","year":"2004","journal-title":"Chest"},{"issue":"02","key":"ref21","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1172\/JCI108941","article-title":"Inhibition of platelet prostaglandin synthetase by oral aspirin","volume":"61","author":"J W Burch","year":"1978","journal-title":"J Clin Invest"},{"key":"ref22","first-page":"349","article-title":"Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group","volume":"2","year":"1988","journal-title":"Lancet"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1136\/bmj.316.7141.1337","article-title":"ISIS-2: 10 year survival among patients with suspected acute myocardial infarction in randomised comparison of intravenous streptokinase, oral aspirin, both, or neither. The ISIS-2 (Second International Study of Infarct Survival) Collaborative Group","volume":"316","author":"C Baigent","year":"1998","journal-title":"BMJ"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(09)60503-1","article-title":"Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials","volume":"373","author":"C Baigent","year":"2009","journal-title":"Lancet"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/bmj.324.7329.71","article-title":"Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients","volume":"324","author":"Antithrombotic Trialists' Collaboration","year":"2002","journal-title":"BMJ"},{"issue":"12","key":"ref26","first-page":"1082","article-title":"2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation","volume":"70","author":"B Ib\u00e1nez","year":"2017","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"issue":"04","key":"ref27","first-page":"e362","article-title":"2013 ACCF\/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"127","author":"P T O'Gara","year":"2013","journal-title":"Circulation"},{"issue":"03","key":"ref28","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1093\/eurheartj\/ehv320","article-title":"2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC)","volume":"37","author":"M Roffi","year":"2016","journal-title":"Eur Heart J"},{"issue":"25","key":"ref29","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1161\/CIR.0000000000000133","article-title":"2014 AHA\/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"130","author":"E A Amsterdam","year":"2014","journal-title":"Circulation"},{"issue":"03","key":"ref30","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1093\/eurheartj\/ehz425","article-title":"2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes","volume":"41","author":"J Knuuti","year":"2020","journal-title":"Eur Heart J"},{"issue":"22","key":"ref31","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1161\/CIR.0b013e318235eb4d","article-title":"AHA\/ACCF Secondary Prevention and Risk Reduction Therapy for Patients with Coronary and other Atherosclerotic Vascular Disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation","volume":"124","author":"S C Smith Jr","year":"2011","journal-title":"Circulation"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/S0140-6736(18)31924-X","article-title":"Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial","volume":"392","author":"J M Gaziano","year":"2018","journal-title":"Lancet"},{"issue":"16","key":"ref33","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1805819","article-title":"Effect of aspirin on cardiovascular events and bleeding in the healthy elderly","volume":"379","author":"J J McNeil","year":"2018","journal-title":"N Engl J Med"},{"issue":"16","key":"ref34","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJMoa1804988","article-title":"Effects of aspirin for primary prevention in persons with diabetes mellitus","volume":"379","author":"L Bowman","year":"2018","journal-title":"N Engl J Med"},{"issue":"16","key":"ref35","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1056\/NEJMoa1800722","article-title":"Effect of aspirin on disability-free survival in the healthy elderly","volume":"379","author":"J J McNeil","year":"2018","journal-title":"N Engl J Med"},{"issue":"03","key":"ref36","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1001\/jama.2018.20578","article-title":"Association of aspirin use for primary prevention with cardiovascular events and bleeding events: a systematic review and meta-analysis","volume":"321","author":"S L Zheng","year":"2019","journal-title":"JAMA"},{"issue":"01","key":"ref37","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1186\/s12916-019-1428-0","article-title":"Aspirin for primary prevention of cardiovascular disease: a meta-analysis with a particular focus on subgroups","volume":"17","author":"G Gelbenegger","year":"2019","journal-title":"BMC Med"},{"issue":"07","key":"ref38","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1093\/eurheartj\/ehy813","article-title":"Efficacy and safety of aspirin for primary prevention of cardiovascular events: a meta-analysis and trial sequential analysis of randomized controlled trials","volume":"40","author":"A N Mahmoud","year":"2019","journal-title":"Eur Heart J"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1016\/S0140-6736(10)60484-9","article-title":"Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies","volume":"375","author":"N Sarwar","year":"2010","journal-title":"Lancet"},{"issue":"12","key":"ref40","doi-asserted-by":"crossref","first-page":"3264","DOI":"10.2337\/diacare.26.12.3264","article-title":"Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial","volume":"26","author":"M Sacco","year":"2003","journal-title":"Diabetes Care"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"a1840","DOI":"10.1136\/bmj.a1840","article-title":"The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease","volume":"337","author":"J Belch","year":"2008","journal-title":"BMJ"},{"issue":"18","key":"ref42","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1001\/jama.2008.623","article-title":"Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial","volume":"300","author":"H Ogawa","year":"2008","journal-title":"JAMA"},{"issue":"10","key":"ref43","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1055\/s-0039-1694774","article-title":"Aspirin and primary prevention in patients with diabetes - a critical evaluation of available randomized trials and meta-analyses","volume":"119","author":"K Schr\u00f6r","year":"2019","journal-title":"Thromb Haemost"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1016\/S0140-6736(19)30541-0","article-title":"The rise and fall of aspirin in the primary prevention of cardiovascular disease","volume":"393","author":"I Raber","year":"2019","journal-title":"Lancet"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.atherosclerosis.2016.05.037","article-title":"2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR)","volume":"252","author":"M F Piepoli","year":"2016","journal-title":"Atherosclerosis"},{"issue":"10","key":"ref46","first-page":"e177","article-title":"2019 ACC\/AHA Guideline on the Primary Prevention of Cardiovascular Disease: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"74","author":"D K Arnett","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"08","key":"ref47","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1161\/CIR.0000000000000230","article-title":"Update on prevention of cardiovascular disease in adults with type 2 diabetes mellitus in light of recent evidence: a scientific statement from the American Heart Association and the American Diabetes Association","volume":"132","author":"C S Fox","year":"2015","journal-title":"Circulation"},{"issue":"06","key":"ref48","doi-asserted-by":"crossref","first-page":"e323","DOI":"10.1016\/S2214-109X(14)70227-X","article-title":"Global causes of maternal death: a WHO systematic analysis","volume":"2","author":"L Say","year":"2014","journal-title":"Lancet Glob Health"},{"issue":"17","key":"ref49","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1007\/s40265-017-0823-0","article-title":"Aspirin for prevention of preeclampsia","volume":"77","author":"A Atallah","year":"2017","journal-title":"Drugs"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1016\/S0140-6736(07)60712-0","article-title":"Antiplatelet agents for prevention of pre-eclampsia: a meta-analysis of individual patient data","volume":"369","author":"L M Askie","year":"2007","journal-title":"Lancet"},{"issue":"02","key":"ref51","first-page":"CD004659","article-title":"Antiplatelet agents for preventing pre-eclampsia and its complications","author":"L Duley","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1097\/AOG.0b013e3181e9322a","article-title":"Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis","volume":"116","author":"E Bujold","year":"2010","journal-title":"Obstet Gynecol"},{"issue":"02","key":"ref53","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.ajog.2016.09.076","article-title":"The role of aspirin dose on the prevention of preeclampsia and fetal growth restriction: systematic review and meta-analysis","volume":"216","author":"S Roberge","year":"2017","journal-title":"Am J Obstet Gynecol"},{"issue":"02","key":"ref54","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ajog.2016.10.016","article-title":"Antiplatelet therapy before or after 16 weeks' gestation for preventing preeclampsia: an individual participant data meta-analysis","volume":"216","author":"S Meher","year":"2017","journal-title":"Am J Obstet Gynecol"},{"key":"ref55","volume-title":"Hypertension in Pregnancy: Diagnosis and Management","author":"National Institute for Health and Care Excellence: Clinical Guidelines","year":"2019"},{"issue":"01","key":"ref56","first-page":"e1","article-title":"ACOG Practice Bulletin No. 202: Gestational hypertension and preeclampsia","volume":"133","year":"2019","journal-title":"Obstet Gynecol"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"S855","DOI":"10.1016\/j.ajog.2017.12.004","article-title":"Evidence-based national guidelines for the management of suspected fetal growth restriction: comparison, consensus, and controversy","volume":"218","author":"L M McCowan","year":"2018","journal-title":"Am J Obstet Gynecol"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S0140-6736(19)32973-3","article-title":"Low-dose aspirin for the prevention of preterm delivery in nulliparous women with a singleton pregnancy (ASPIRIN): a randomised, double-blind, placebo-controlled trial","volume":"395","author":"M K Hoffman","year":"2020","journal-title":"Lancet"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.thromres.2019.02.009","article-title":"A changing landscape: temporal trends in incidence and characteristics of patients hospitalized with venous thromboembolism 2006-2015","volume":"176","author":"A M M\u00fcnster","year":"2019","journal-title":"Thromb Res"},{"issue":"01","key":"ref60","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-125-1-199607010-00001","article-title":"The long-term clinical course of acute deep venous thrombosis","volume":"125","author":"P Prandoni","year":"1996","journal-title":"Ann Intern Med"},{"issue":"21","key":"ref61","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1056\/NEJMoa1114238","article-title":"Aspirin for preventing the recurrence of venous thromboembolism","volume":"366","author":"C Becattini","year":"2012","journal-title":"N Engl J Med"},{"issue":"21","key":"ref62","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1056\/NEJMoa1210384","article-title":"Low-dose aspirin for preventing recurrent venous thromboembolism","volume":"367","author":"T A Brighton","year":"2012","journal-title":"N Engl J Med"},{"issue":"05","key":"ref63","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.thromres.2015.02.032","article-title":"Comparative efficacy and safety of anticoagulants and aspirin for extended treatment of venous thromboembolism: a network meta-analysis","volume":"135","author":"D M Sobieraj","year":"2015","journal-title":"Thromb Res"},{"issue":"13","key":"ref64","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1056\/NEJMoa1700518","article-title":"Rivaroxaban or aspirin for extended treatment of venous thromboembolism","volume":"376","author":"J I Weitz","year":"2017","journal-title":"N Engl J Med"},{"issue":"05","key":"ref65","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.diabet.2019.11.002","article-title":"Determinants of aspirin resistance in patients with type 2 diabetes","volume":"46","author":"E Paven","year":"2020","journal-title":"Diabetes Metab"},{"issue":"05","key":"ref66","doi-asserted-by":"crossref","first-page":"e0126767","DOI":"10.1371\/journal.pone.0126767","article-title":"Determinants of reduced antiplatelet effect of aspirin in patients with stable coronary artery disease","volume":"10","author":"S B Larsen","year":"2015","journal-title":"PLoS One"},{"issue":"05","key":"ref67","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1161\/01.CIR.0000081770.51929.5A","article-title":"Functional and biochemical evaluation of platelet aspirin resistance after coronary artery bypass surgery","volume":"108","author":"N Zimmermann","year":"2003","journal-title":"Circulation"},{"issue":"15","key":"ref68","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1001\/archinte.167.15.1593","article-title":"Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta-analysis","volume":"167","author":"J D Snoep","year":"2007","journal-title":"Arch Intern Med"},{"key":"ref69","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1136\/bmj.39430.529549.BE","article-title":"Aspirin \u201cresistance\u201d and risk of cardiovascular morbidity: systematic review and meta-analysis","volume":"336","author":"G Krasopoulos","year":"2008","journal-title":"BMJ"},{"issue":"05","key":"ref70","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.ahj.2009.11.033","article-title":"Hypothesis formulation from subgroup analyses: nonadherence or nonsteroidal anti-inflammatory drug use explains the lack of clinical benefit of aspirin on first myocardial infarction attributed to \u201caspirin resistance\u201d","volume":"159","author":"C H Hennekens","year":"2010","journal-title":"Am Heart J"},{"issue":"05","key":"ref71","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/j.1755-5922.2010.00188.x","article-title":"Aspirin resistance and compliance with therapy","volume":"29","author":"J Dawson","year":"2011","journal-title":"Cardiovasc Ther"},{"issue":"05","key":"ref72","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/j.ahj.2009.02.013","article-title":"Aspirin noncompliance is the major cause of \u201caspirin resistance\u201d in patients undergoing coronary stenting","volume":"157","author":"T Cuisset","year":"2009","journal-title":"Am Heart J"},{"issue":"04","key":"ref73","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1160\/TH05-04-0889","article-title":"Effect of compliance and dosage adaptation of long term aspirin on platelet function with PFA-100 in patients after myocardial infarction","volume":"94","author":"K W von Pape","year":"2005","journal-title":"Thromb Haemost"},{"issue":"02","key":"ref74","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.ijcard.2014.05.013","article-title":"24-hour antiplatelet effect of aspirin in patients with previous definite stent thrombosis","volume":"175","author":"M W\u00fcrtz","year":"2014","journal-title":"Int J Cardiol"},{"issue":"02","key":"ref75","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1160\/TH10-02-0082","article-title":"24-hour time-dependent aspirin efficacy in patients with stable coronary artery disease","volume":"105","author":"P Henry","year":"2011","journal-title":"Thromb Haemost"},{"issue":"03","key":"ref76","doi-asserted-by":"crossref","first-page":"230","DOI":"10.3109\/09537104.2014.901497","article-title":"Reduced antiplatelet effect of aspirin during 24\u2009hours in patients with coronary artery disease and type 2 diabetes","volume":"26","author":"K H Christensen","year":"2015","journal-title":"Platelets"},{"issue":"09","key":"ref77","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.jacc.2008.05.031","article-title":"Role of reticulated platelets and platelet size heterogeneity on platelet activity after dual antiplatelet therapy with aspirin and clopidogrel in patients with stable coronary artery disease","volume":"52","author":"S Guthikonda","year":"2008","journal-title":"J Am Coll Cardiol"},{"issue":"05","key":"ref78","first-page":"930","article-title":"Relationship between high platelet turnover and platelet function in high-risk patients with coronary artery disease on dual antiplatelet therapy","volume":"99","author":"F Cesari","year":"2008","journal-title":"Thromb Haemost"},{"issue":"03","key":"ref79","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1080\/09537104.2018.1430356","article-title":"Once- versus twice-daily aspirin treatment in patients with essential thrombocytosis","volume":"30","author":"M L Larsen","year":"2019","journal-title":"Platelets"},{"issue":"05","key":"ref80","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1136\/hrt.2009.181107","article-title":"The antiplatelet effect of aspirin is reduced by proton pump inhibitors in patients with coronary artery disease","volume":"96","author":"M W\u00fcrtz","year":"2010","journal-title":"Heart"},{"key":"ref81","doi-asserted-by":"crossref","first-page":"d2690","DOI":"10.1136\/bmj.d2690","article-title":"Proton pump inhibitor use and risk of adverse cardiovascular events in aspirin treated patients with first time myocardial infarction: nationwide propensity score matched study","volume":"342","author":"M Charlot","year":"2011","journal-title":"BMJ"},{"issue":"25","key":"ref82","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa003199","article-title":"Cyclooxygenase inhibitors and the antiplatelet effects of aspirin","volume":"345","author":"F Catella-Lawson","year":"2001","journal-title":"N Engl J Med"},{"issue":"08","key":"ref83","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/j.jacc.2005.01.045","article-title":"Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects","volume":"45","author":"M L Capone","year":"2005","journal-title":"J Am Coll Cardiol"},{"issue":"23","key":"ref84","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1093\/eurheartj\/eht042","article-title":"Expert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapy","volume":"34","author":"S Agewall","year":"2013","journal-title":"Eur Heart J"},{"issue":"06","key":"ref85","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.jacc.2004.08.070","article-title":"Aspirin resistance and atherothrombotic disease","volume":"46","author":"P J Mason","year":"2005","journal-title":"J Am Coll Cardiol"},{"issue":"14","key":"ref86","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1093\/eurheartj\/ehm226","article-title":"A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease","volume":"28","author":"M Lordkipanidz\u00e9","year":"2007","journal-title":"Eur Heart J"},{"issue":"06","key":"ref87","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1160\/TH09-08-0527","article-title":"A comparison of platelet function tests and thromboxane metabolites to evaluate aspirin response in healthy individuals and patients with coronary artery disease","volume":"103","author":"E L Grove","year":"2010","journal-title":"Thromb Haemost"},{"issue":"02","key":"ref88","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ahj.2006.10.040","article-title":"Prevalence of persistent platelet reactivity despite use of aspirin: a systematic review","volume":"153","author":"M M Hovens","year":"2007","journal-title":"Am Heart J"},{"issue":"11","key":"ref89","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1002\/clc.22031","article-title":"Aspirin resistance: current status and role of tailored therapy","volume":"35","author":"J Grinstein","year":"2012","journal-title":"Clin Cardiol"},{"issue":"06","key":"ref90","first-page":"1077","article-title":"Can we improve the efficacy of low-dose aspirin?","volume":"112","author":"E L Grove","year":"2014","journal-title":"Thromb Haemost"},{"issue":"04","key":"ref91","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.ahj.2012.06.008","article-title":"Biological efficacy of twice daily aspirin in type 2 diabetic patients with coronary artery disease","volume":"164","author":"J G Dillinger","year":"2012","journal-title":"Am Heart J"},{"issue":"02","key":"ref92","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1161\/CIRCINTERVENTIONS.110.960187","article-title":"Pharmacodynamic effects of different aspirin dosing regimens in type 2 diabetes mellitus patients with coronary artery disease","volume":"4","author":"D Capodanno","year":"2011","journal-title":"Circ Cardiovasc Interv"},{"issue":"03","key":"ref93","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1160\/TH11-04-0216","article-title":"Twice daily dosing of aspirin improves platelet inhibition in whole blood in patients with type 2 diabetes mellitus and micro- or macrovascular complications","volume":"106","author":"G Spectre","year":"2011","journal-title":"Thromb Haemost"},{"issue":"02","key":"ref94","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1111\/dme.12828","article-title":"Randomized controlled trial comparing impact on platelet reactivity of twice-daily with once-daily aspirin in people with Type 2 diabetes","volume":"33","author":"M A Bethel","year":"2016","journal-title":"Diabet Med"},{"issue":"03","key":"ref95","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1111\/jth.12832","article-title":"Multiple daily doses of acetyl-salicylic acid (ASA) overcome reduced platelet response to once-daily ASA after coronary artery bypass graft surgery: a pilot randomized controlled trial","volume":"13","author":"J S Paikin","year":"2015","journal-title":"J Thromb Haemost"},{"issue":"05","key":"ref96","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1111\/jth.13667","article-title":"Once versus twice daily aspirin after coronary bypass surgery: a randomized trial","volume":"15","author":"J S Paikin","year":"2017","journal-title":"J Thromb Haemost"},{"issue":"01","key":"ref97","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.thromres.2011.09.017","article-title":"Twice daily aspirin to improve biological aspirin efficacy in patients with essential thrombocythemia","volume":"129","author":"J G Dillinger","year":"2012","journal-title":"Thromb Res"},{"issue":"15","key":"ref98","doi-asserted-by":"crossref","first-page":"3595","DOI":"10.1182\/blood-2011-06-359224","article-title":"Aspirin-insensitive thromboxane biosynthesis in essential thrombocythemia is explained by accelerated renewal of the drug target","volume":"119","author":"S Pascale","year":"2012","journal-title":"Blood"},{"issue":"04","key":"ref99","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/clc.12101","article-title":"Relation between time of symptom onset of ST-segment elevation myocardial infarction and patient baseline characteristics: from the National Cardiovascular Data Registry","volume":"36","author":"O Mogabgab","year":"2013","journal-title":"Clin Cardiol"},{"key":"ref100","doi-asserted-by":"crossref","first-page":"291S","DOI":"10.1016\/S0895-7061(01)02174-4","article-title":"Cyclic and circadian variations in cardiovascular events","volume":"14","author":"W J Elliot","year":"2001","journal-title":"Am J Hypertens"},{"key":"ref101","doi-asserted-by":"crossref","first-page":"84","DOI":"10.3389\/fcvm.2019.00084","article-title":"Circadian rhythm of cardiovascular disease: the potential of chronotherapy with aspirin","volume":"6","author":"M Buurma","year":"2019","journal-title":"Front Cardiovasc Med"},{"issue":"24","key":"ref102","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1056\/NEJM198706113162405","article-title":"Concurrent morning increase in platelet aggregability and the risk of myocardial infarction and sudden cardiac death","volume":"316","author":"G H Tofler","year":"1987","journal-title":"N Engl J Med"},{"issue":"06","key":"ref103","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1160\/th14-05-0453","article-title":"Effect of aspirin intake at bedtime versus on awakening on circadian rhythm of platelet reactivity. A randomised cross-over trial","volume":"112","author":"T N Bonten","year":"2014","journal-title":"Thromb Haemost"},{"issue":"07","key":"ref104","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1080\/09537104.2018.1528347","article-title":"Aspirin intake in the morning is associated with suboptimal platelet inhibition, as measured by serum Thromboxane B2, during infarct-prone early-morning hours","volume":"30","author":"C Racca","year":"2019","journal-title":"Platelets"},{"issue":"04","key":"ref105","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1161\/HYPERTENSIONAHA.114.04980","article-title":"Time-dependent effects of aspirin on blood pressure and morning platelet reactivity: a randomized cross-over trial","volume":"65","author":"T N Bonten","year":"2015","journal-title":"Hypertension"},{"issue":"06","key":"ref106","doi-asserted-by":"crossref","first-page":"727","DOI":"10.5603\/CJ.a2018.0142","article-title":"The effect of acetylsalicylic acid dosed at bedtime on the anti-aggregation effect in patients with coronary heart disease and arterial hypertension: a randomized, controlled trial","volume":"26","author":"B Krasi\u0144ska","year":"2019","journal-title":"Cardiol J"},{"issue":"04","key":"ref107","doi-asserted-by":"crossref","first-page":"351","DOI":"10.3109\/09537104.2015.1107536","article-title":"Evening intake of aspirin is associated with a more stable 24-h platelet inhibition compared to morning intake: a study in chronic aspirin users","volume":"27","author":"J J van Diemen","year":"2016","journal-title":"Platelets"},{"issue":"03","key":"ref108","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1056\/NEJM198007173030305","article-title":"Endoscopic evaluation of the effects of aspirin, buffered aspirin, and enteric-coated aspirin on gastric and duodenal mucosa","volume":"303","author":"F L Lanza","year":"1980","journal-title":"N Engl J Med"},{"issue":"01","key":"ref109","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/j.1365-2125.1991.tb05616.x","article-title":"Aspirin-induced gastric mucosal damage: prevention by enteric-coating and relation to prostaglandin synthesis","volume":"32","author":"A B Hawthorne","year":"1991","journal-title":"Br J Clin Pharmacol"},{"issue":"08","key":"ref110","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1046\/j.1365-2036.1999.00588.x","article-title":"Enteric coating of aspirin significantly decreases gastroduodenal mucosal lesions","volume":"13","author":"H G Dammann","year":"1999","journal-title":"Aliment Pharmacol Ther"},{"issue":"02","key":"ref111","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1046\/j.1365-2036.1999.00470.x","article-title":"Protection of human gastric mucosa against aspirin-enteric coating or dose reduction?","volume":"13","author":"A T Cole","year":"1999","journal-title":"Aliment Pharmacol Ther"},{"issue":"02","key":"ref112","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/j.1472-8206.2000.tb00404.x","article-title":"Gastroduodenal tolerability of medium dose enteric-coated aspirin: a placebo controlled endoscopic study of a new enteric-coated formulation versus regular formulation in healthy volunteers","volume":"14","author":"H Blondon","year":"2000","journal-title":"Fundam Clin Pharmacol"},{"issue":"02","key":"ref113","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1038\/ajg.2010.436","article-title":"Low-dose aspirin-induced ulceration is attenuated by aspirin-phosphatidylcholine: a randomized clinical trial","volume":"106","author":"B Cryer","year":"2011","journal-title":"Am J Gastroenterol"},{"issue":"10","key":"ref114","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.dld.2012.05.016","article-title":"Differences in the severity of small bowel mucosal injury based on the type of aspirin as evaluated by capsule endoscopy","volume":"44","author":"H Endo","year":"2012","journal-title":"Dig Liver Dis"},{"issue":"09","key":"ref115","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1111\/j.1572-0241.2000.02248.x","article-title":"Risk of upper gastrointestinal bleeding associated with use of low-dose aspirin","volume":"95","author":"H T S\u00f8rensen","year":"2000","journal-title":"Am J Gastroenterol"},{"key":"ref116","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/S0140-6736(96)01254-8","article-title":"Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product","volume":"348","author":"J P Kelly","year":"1996","journal-title":"Lancet"},{"issue":"02","key":"ref117","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1097\/00043798-199604000-00013","article-title":"Anti-platelet effects of 100\u2009mg alternate day oral aspirin: a randomized, double-blind, placebo-controlled trial of regular and enteric coated formulations in men and women","volume":"3","author":"P M Ridker","year":"1996","journal-title":"J Cardiovasc Risk"},{"issue":"05","key":"ref118","doi-asserted-by":"crossref","first-page":"976.e7","DOI":"10.1016\/j.ahj.2006.02.017","article-title":"Lack of effect of enteric coating on aspirin-induced inhibition of platelet aggregation in healthy volunteers","volume":"151","author":"J Karha","year":"2006","journal-title":"Am Heart J"},{"issue":"06","key":"ref119","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.amjcard.2006.03.071","article-title":"Effect of aspirin dose, preparation, and withdrawal on platelet response in normal volunteers","volume":"98","author":"J L Coleman","year":"2006","journal-title":"Am J Cardiol"},{"issue":"03","key":"ref120","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1161\/CIRCULATIONAHA.112.117283","article-title":"Drug resistance and pseudoresistance: an unintended consequence of enteric coating aspirin","volume":"127","author":"T Grosser","year":"2013","journal-title":"Circulation"},{"issue":"06","key":"ref121","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.jacc.2016.11.050","article-title":"Enteric coating and aspirin nonresponsiveness in patients with type 2 diabetes mellitus","volume":"69","author":"D L Bhatt","year":"2017","journal-title":"J Am Coll Cardiol"},{"issue":"08","key":"ref122","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1161\/01.STR.0000231683.43347.ec","article-title":"Effect of enteric coating on antiplatelet activity of low-dose aspirin in healthy volunteers","volume":"37","author":"D Cox","year":"2006","journal-title":"Stroke"},{"issue":"10","key":"ref123","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1111\/j.1538-7836.2010.03997.x","article-title":"The role of weight and enteric coating on aspirin response in cardiovascular patients","volume":"8","author":"A Peace","year":"2010","journal-title":"J Thromb Haemost"},{"issue":"07","key":"ref124","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/j.jacc.2005.06.058","article-title":"Platelet response to low-dose enteric-coated aspirin in patients with stable cardiovascular disease","volume":"46","author":"A O Maree","year":"2005","journal-title":"J Am Coll Cardiol"},{"issue":"03","key":"ref125","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/eurheartj\/ehx419","article-title":"2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"39","author":"M Valgimigli","year":"2018","journal-title":"Eur Heart J"},{"issue":"10","key":"ref126","doi-asserted-by":"crossref","first-page":"e123","DOI":"10.1161\/CIR.0000000000000404","article-title":"2016 ACC\/AHA Guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines: an update of the 2011 ACCF\/AHA\/SCAI Guideline for Percutaneous Coronary Intervention, 2011 ACCF\/AHA Guideline for Coronary Artery Bypass Graft Surgery, 2012 ACC\/AHA\/ACP\/AATS\/PCNA\/SCAI\/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease, 2013 ACCF\/AHA Guideline for the Management of ST-Elevation Myocardial Infarction, 2014 AHA\/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes, and 2014 ACC\/AHA Guideline on Perioperative Cardiovascular Evaluation and Management of Patients Undergoing Noncardiac Surgery","volume":"134","author":"G N Levine","year":"2016","journal-title":"Circulation"},{"issue":"04","key":"ref127","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1055\/s-0039-3399567","article-title":"Benefits and harm of treatment with P2Y12 inhibitors beyond 12 months in patients with coronary artery disease","volume":"46","author":"M L Larsen","year":"2020","journal-title":"Semin Thromb Hemost"},{"key":"ref128","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1016\/S0140-6736(09)61751-7","article-title":"Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data","volume":"374","author":"R S\u00f8rensen","year":"2009","journal-title":"Lancet"},{"issue":"09","key":"ref129","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1080\/14656566.2017.1329822","article-title":"Antithrombotic strategies for preventing long-term major adverse cardiovascular events in patients with non-valvular atrial fibrillation who undergo percutaneous coronary intervention","volume":"18","author":"M Pareek","year":"2017","journal-title":"Expert Opin Pharmacother"},{"issue":"03","key":"ref130","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/nrc.2016.4","article-title":"Aspirin and colorectal cancer: the promise of precision chemoprevention","volume":"16","author":"D A Drew","year":"2016","journal-title":"Nat Rev Cancer"},{"issue":"02","key":"ref131","doi-asserted-by":"crossref","first-page":"C176","DOI":"10.1152\/ajpcell.00196.2016","article-title":"Aspirin therapy reduces the ability of platelets to promote colon and pancreatic cancer cell proliferation: implications for the oncoprotein c-MYC","volume":"312","author":"A Mitrugno","year":"2017","journal-title":"Am J Physiol Cell Physiol"},{"issue":"08","key":"ref132","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1080\/09537104.2018.1492105","article-title":"Aspirin, platelet inhibition and cancer prevention","volume":"29","author":"P Patrignani","year":"2018","journal-title":"Platelets"},{"issue":"05","key":"ref133","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/S1470-2045(12)70112-2","article-title":"Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials","volume":"13","author":"A M Algra","year":"2012","journal-title":"Lancet Oncol"},{"issue":"02","key":"ref134","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1158\/1940-6207.CAPR-11-0391","article-title":"Aspirin in the chemoprevention of colorectal neoplasia: an overview","volume":"5","author":"A T Chan","year":"2012","journal-title":"Cancer Prev Res (Phila)"},{"key":"ref135","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1016\/S0140-6736(11)61049-0","article-title":"Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial","volume":"378","author":"J Burn","year":"2011","journal-title":"Lancet"},{"issue":"02","key":"ref136","doi-asserted-by":"crossref","first-page":"77","DOI":"10.7326\/0003-4819-159-2-201307160-00002","article-title":"Alternate-day, low-dose aspirin and cancer risk: long-term observational follow-up of a randomized trial","volume":"159","author":"N R Cook","year":"2013","journal-title":"Ann Intern Med"},{"key":"ref137","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1016\/S0140-6736(10)61543-7","article-title":"Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials","volume":"376","author":"P M Rothwell","year":"2010","journal-title":"Lancet"},{"issue":"10","key":"ref138","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1056\/NEJMoa021735","article-title":"A randomized trial of aspirin to prevent colorectal adenomas","volume":"348","author":"J A Baron","year":"2003","journal-title":"N Engl J Med"},{"issue":"10","key":"ref139","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa021633","article-title":"A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer","volume":"348","author":"R S Sandler","year":"2003","journal-title":"N Engl J Med"},{"issue":"02","key":"ref140","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/S0016-5085(03)00887-4","article-title":"Daily soluble aspirin and prevention of colorectal adenoma recurrence: one-year results of the APACC trial","volume":"125","author":"R Benamouzig","year":"2003","journal-title":"Gastroenterology"},{"issue":"03","key":"ref141","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1053\/j.gastro.2018.11.063","article-title":"Aspirin and cancer prevention in the elderly: Where do we go from here?","volume":"156","author":"A T Chan","year":"2019","journal-title":"Gastroenterology"},{"issue":"12","key":"ref142","doi-asserted-by":"crossref","first-page":"836","DOI":"10.7326\/M16-0577","article-title":"Aspirin use for the primary prevention of cardiovascular disease and colorectal cancer: U.S. Preventive Services Task Force Recommendation Statement","volume":"164","author":"K Bibbins-Domingo","year":"2016","journal-title":"Ann Intern Med"},{"issue":"01","key":"ref143","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1186\/s12885-018-4156-5","article-title":"Associations between aspirin use and the risk of cancers: a meta-analysis of observational studies","volume":"18","author":"Y Qiao","year":"2018","journal-title":"BMC Cancer"},{"issue":"11","key":"ref144","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1056\/NEJMoa1912035","article-title":"Association of aspirin with hepatocellular carcinoma and liver-related mortality","volume":"382","author":"T G Simon","year":"2020","journal-title":"N Engl J Med"},{"issue":"04","key":"ref145","doi-asserted-by":"crossref","first-page":"e0152402","DOI":"10.1371\/journal.pone.0152402","article-title":"Aspirin in the treatment of cancer: reductions in metastatic spread and in mortality: a systematic review and meta-analyses of published studies","volume":"11","author":"P C Elwood","year":"2016","journal-title":"PLoS One"},{"issue":"11","key":"ref146","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1136\/gutjnl-2013-305827","article-title":"The preventive effects of low-dose enteric-coated aspirin tablets on the development of colorectal tumours in Asian patients: a randomised trial","volume":"63","author":"H Ishikawa","year":"2014","journal-title":"Gut"},{"key":"ref147","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.ctrv.2016.12.008","article-title":"The mortality reducing effect of aspirin in colorectal cancer patients: Interpreting the evidence","volume":"55","author":"M A Frouws","year":"2017","journal-title":"Cancer Treat Rev"},{"issue":"10","key":"ref148","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1093\/jjco\/hyz106","article-title":"Efficacy of aspirin for stage III colorectal cancer: a randomized double-blind placebo-controlled trial (JCOG1503C, EPISODE-III trial)","volume":"49","author":"K Miyamoto","year":"2019","journal-title":"Jpn J Clin Oncol"}],"container-title":["Seminars in Thrombosis and Hemostasis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0041-1726096.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,5]],"date-time":"2021-10-05T00:51:21Z","timestamp":1633395081000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0041-1726096"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,15]]},"references-count":148,"journal-issue":{"issue":"07","published-online":{"date-parts":[[2021,10,4]]},"published-print":{"date-parts":[[2021,10]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0041-1726096","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0094-6176","1098-9064"],"issn-type":[{"value":"0094-6176","type":"print"},{"value":"1098-9064","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,15]]}}}